1Satoh SH,Suzuki I,Kegaki I,et al.The effects of HA 1077 on the cerebral circulation after subarachnoib haemorrhage in dogs[J].Acta Neurochir(Wien),1991,110(1):185.
1Nakamura K,Nishimura J,Hirano K,et al.Hydroxyfasudil,an active metabolice of fasudil hydrochloride,relaxes the rabbit basilar artery by disinibition of myosin light chain phosphatase.J Cereb Blood Flow Metab,2001,21:876-885.
2Masumoto N,Tanabe Y,Saito M,et al.Attenuation of pressure-induced myogenic contraction and tyrosine phosphorylation by fasudil,a cerebral vasodilator,in rat cerebral artery.British journal of pharmacology,2000,130:219-230.
3Takanashi Y,Ishida T,Meguro T,et al.A novel drug delivery system as prophylaxis for cerebral vasospasm.Acta Neurochir,2001,(Suppl) 77:213-215.
4Masaoka H,Takasato Y,Nojiri T,et al.Clinic effect of fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage.Acta Neurochir,2001,(Suppl) 77:209-221.
5Miriam M T,Bernhard W,Peter M S,et al.Systematic review of the prevention of delayed ischemic neurological deficits with hypertension,hypervolemia,and hemodilution therapy following subarachnoid hemorrhage.J Neurosurg,2003,98:978-984.
7Sasaki Y,Suzuki M,Hidaka H.The noval and specific rhokinase inhibitor (s)-(+) -2-Methyl-1-[(4-methyl-5 -isoquinoline) sulfony] -Homopiperazine as a probing molecule for rho-kinase-invlved pathway.Phrmacology & Therapeutics,2002,93:225-232.
8Satoh Sh,Suzuki I,Ikegaki I,et al.The effects of HA 1077on the cerebral circulation after subarachnoid haemorrhage in dogs.Acta Neurochir (Wien),1991,110:185-188.
9Shibuya M,Suzuki Y,Sugita K,et al.Effect of AT877 on cerebral vasospasm after aneurysmal subaracnoid hemorrhage.J Neurosurg,1992,76:571-577.
10Shibuya M,Asano T,Sasaki Y.Effect of fasudil HCl,a protein kinase inhibitor,on cerebral vasospasm.Acta Neurochir,2000,(Suppl) 77:201-204.
7Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trails[J]. BMJ, 2001,323 ( 1 ) : 42.
8Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008[Z]. The Cochrane Collaboration, 2008.
9Higgins JP, Thompson SG.Quantifying heterogeneity in a Meta-analysis[J]. Stat Med, 2002,21 ( 11 ) : 1 539.
10Julian PT Higgins, Douglas G Altman. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009.
